lenalidomide has been researched along with dapsone in 5 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (dapsone) | Trials (dapsone) | Recent Studies (post-2010) (dapsone) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 5,116 | 379 | 862 |
| Protein | Taxonomy | lenalidomide (IC50) | dapsone (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 0.42 | |
| Dihydrofolate reductase | Pneumocystis carinii | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bonsmann, G; Kuhn, A; Ruland, V | 1 |
| Aberer, E; Bata-Csörgő, Z; Caproni, M; Dreher, A; Frances, C; Gläser, R; Klötgen, HW; Kuhn, A; Landmann, A; Marinovic, B; Nyberg, F; Olteanu, R; Ranki, A; Szepietowski, JC; Volc-Platzer, B | 1 |
| Nutan, F; Ortega-Loayza, AG | 1 |
3 review(s) available for lenalidomide and dapsone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cutaneous lupus erythematosus: update of therapeutic options part II.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Clofazimine; Cyclophosphamide; Cyclosporine; Dapsone; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferon-alpha; Isoxazoles; Leflunomide; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Rituximab; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
Cutaneous Lupus: A Brief Review of Old and New Medical Therapeutic Options.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antimalarials; Calcineurin Inhibitors; Dapsone; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Retinoids; Thalidomide | 2017 |
2 other study(ies) available for lenalidomide and dapsone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).
Topics: Adrenal Cortex Hormones; Antimalarials; Biological Products; Calcineurin Inhibitors; Consensus; Dapsone; Humans; Immunosuppressive Agents; Lenalidomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Practice Guidelines as Topic; Retinoids; Thalidomide | 2017 |